Literature DB >> 17318387

Modafinil's use in combating interferon-induced fatigue.

Kari A Martin1, Lois E Krahn, Vijayan Balan, Marianne J Rosati.   

Abstract

Interferon (IFN) is an effective agent in the treatment of chronic viral hepatitis C. A variety of adverse neuropsychiatric effects including anxiety, depression, delirium, psychoses, and mania complicates its usage. IFN-alpha-induced depression is presumed to be composed of two overlapping syndromes: a depression-specific syndrome characterized by depressed mood, anxiety, and cognitive complaints, and a neurovegetative syndrome consisting of fatigue, anorexia, somatic pain complaints, and psychomotor retardation [1]. Our results show that depression-specific symptoms peak at 12 weeks of IFN therapy and respond well to serotoninergic antidepressants [2]. We conclude that neurovegetative symptoms are relatively treatment refractory to antidepressants, occur early in the course of treatment, and tend to persist for the duration of therapy [1].

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17318387     DOI: 10.1007/s10620-006-9519-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  12 in total

1.  Fatigue in patients with chronic hepatitis C.

Authors:  T Poynard; P Cacoub; V Ratziu; R P Myers; M H Dezailles; A Mercadier; P Ghillani; F Charlotte; J C Piette; J Moussalli
Journal:  J Viral Hepat       Date:  2002-07       Impact factor: 3.728

2.  Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease.

Authors:  Charles H Adler; John N Caviness; Joseph G Hentz; Marlene Lind; Judy Tiede
Journal:  Mov Disord       Date:  2003-03       Impact factor: 10.338

3.  Ethical challenges in the care of persons with hepatitis C infection: a pilot study to enhance informed consent with veterans.

Authors:  Cynthia M A Geppert; Elizabeth Dettmer; Antonie Jakiche
Journal:  Psychosomatics       Date:  2005 Sep-Oct       Impact factor: 2.386

4.  Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study.

Authors:  K W Rammohan; J H Rosenberg; D J Lynn; A M Blumenfeld; C P Pollak; H N Nagaraja
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

5.  The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus.

Authors:  L B Krupp; N G LaRocca; J Muir-Nash; A D Steinberg
Journal:  Arch Neurol       Date:  1989-10

6.  Is fatigue an independent and persistent symptom in patients with Parkinson disease?

Authors:  G Alves; T Wentzel-Larsen; J P Larsen
Journal:  Neurology       Date:  2004-11-23       Impact factor: 9.910

Review 7.  Neuropsychiatric adverse effects of interferon-alpha: recognition and management.

Authors:  Charles L Raison; Marina Demetrashvili; Lucile Capuron; Andrew H Miller
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

8.  Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFN alpha-induced depression.

Authors:  Peter Hauser
Journal:  Gastroenterol Clin North Am       Date:  2004-03       Impact factor: 3.806

9.  The impact of fatigue on patients with multiple sclerosis.

Authors:  J D Fisk; A Pontefract; P G Ritvo; C J Archibald; T J Murray
Journal:  Can J Neurol Sci       Date:  1994-02       Impact factor: 2.104

Review 10.  Clinical pharmacokinetic profile of modafinil.

Authors:  Philmore Robertson; Edward T Hellriegel
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more
  6 in total

1.  Management of Psychiatric Disease in Hepatitis C Treatment Candidates.

Authors:  Francis Lotrich
Journal:  Curr Hepat Rep       Date:  2010-04-06

Review 2.  Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.

Authors:  Mark S Sulkowski; Curtis Cooper; Bela Hunyady; Jidong Jia; Pavel Ogurtsov; Markus Peck-Radosavljevic; Mitchell L Shiffman; Cihan Yurdaydin; Olav Dalgard
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-03-08       Impact factor: 46.802

Review 3.  Chronic fatigue syndrome: Harvey and Wessely's (bio)psychosocial model versus a bio(psychosocial) model based on inflammatory and oxidative and nitrosative stress pathways.

Authors:  Michael Maes; Frank N M Twisk
Journal:  BMC Med       Date:  2010-06-15       Impact factor: 8.775

4.  Psychiatric clearance for patients started on interferon-alpha-based therapies.

Authors:  Francis E Lotrich
Journal:  Am J Psychiatry       Date:  2013-06       Impact factor: 18.112

Review 5.  Depression, fatigue and neurocognitive deficits in chronic hepatitis C.

Authors:  Sern Wei Yeoh; Alex C N Holmes; Michael M Saling; Ian P Everall; Amanda J Nicoll
Journal:  Hepatol Int       Date:  2018-06-21       Impact factor: 6.047

6.  Neuropsychiatric and psychosocial issues of patients with hepatitis C infection: a selective literature review.

Authors:  Amirhossein Modabbernia; Hossein Poustchi; Reza Malekzadeh
Journal:  Hepat Mon       Date:  2013-01-07       Impact factor: 0.660

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.